Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Development of a global diagnostic ecosystem for detecting and monitoring emergency-prone pathogens across species and in a unified way

Project description

Innovative solutions for global health crises

Rapid and accurate diagnostics remain a critical challenge amidst the persistent threat of global health crises. Timely identification of emerging pathogens is hindered by limited access to sophisticated laboratory facilities, particularly in resource-constrained regions. This gap in diagnostics not only delays response efforts, but also exacerbates the spread of infectious diseases. In this context, the EU-funded UniHealth project pioneers in vitro diagnostic solutions for point-of-care application. It aims to develop and deliver two devices and six molecular assays for emerging pathogens. UniHealth ensures connectivity and surveillance capabilities. Using the isothermal amplification method for RNA-target detection, it guarantees specificity even in crude samples. Assays cover a range of viruses, including Corona and influenza along with specific ones such as Zika and West Nile.

Objective

We aim to contribute to global diagnostics and preparedness for the next health crisis by developing in vitro diagnostic devices and methodologies for application at the point-of-care. For this purpose, mature as well as novel technologies and assays will be developed, addressing all pandemic preparedness requirements; i.e. with regards to assay characteristics and ability to assimilate new targets as well as platform ease of use and connectivity fulfilling manufacturing and regulatory requirements. In the 36 months of the project, we intend to develop and deliver two IVDR certified devices and six molecular assays for emerging pathogens detection at the point-of-care. We will build on a recent commercial success during the COVID-19 pandemic, the Pebble platform and an innovative pocket-size device to be developed within the project, both providing capability for connectivity and surveillance. For the RNA-targets detection, we will employ a recently developed amplification method (DAMP) demonstrated to have a high specificity in crude samples. Three broad assays will be developed for screening of viruses belonging in one of the families of Corona, Influenza or Arboviruses, and three specific ones for Dengue, Zika and West Nile viruses, all according to IVDR-recommendations. Importantly the above six assays will be tested using samples from humans, animals and during field-monitoring of mosquito populations, providing a solution for the One Health initiative. For the development of accessible diagnostic tools, the UniHealth consortium consist of expert researchers, technologists, doctors, social scientists, regulators, innovators and biomedical device providers within the areas of diagnostics and pandemics. The high degree of UniHealth’s innovation and the co-development of solutions with global partners and end-users will expand the visibly and uptake of the project results to a global level leading to a high preparedness and an economic and social success.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-IA - HORIZON Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2023-TOOL-05

See all projects funded under this call

Coordinator

IDRYMA TECHNOLOGIAS KAI EREVNAS
Net EU contribution
€ 1 283 488,75
Address
N PLASTIRA STR 100
700 13 IRAKLEIO
Greece
Region
Νησιά Αιγαίου Κρήτη Ηράκλειο
Activity type
Research Organisations
Links
Total cost
€ 1 283 488,75

Participants (8)

Partners (2)